NEW YORK, Feb. 14, 2013 /PRNewswire/ -- Male enhancement company Maxoderm, available online at http://www.Maxoderm.com, is now showcasing Vivaxa, one of its many available male creams. The Vivaxa formula is designed with special ingredients for users who wish to experience increased stamina in the bedroom.
"An abundance of male enhancement products are now available on the market, which may make singling out the effective ones quite difficult. However, learning about the products' key ingredients is a good way to separate useful products from the rest. The result of any effective male enhancement product should be: enhanced libido, stamina, mood and size. L-arginine is thought to improve the action of nitric oxide and relax the muscles that surround blood vessels supporting the penis. This ingredient is essential to penile performance, and is found in Vivaxa," said Rica Lewis, Livestrong.com health and wellness contributor.
The patent-pending formula for Vivaxa includes a unique peptide sequence to create first-use results unlike those provided by similar male delay creams. Vivaxa is odorless and includes arginine, an amino acid shown to diminish hyper-excitability of the skin, which helps to extend the duration of intimate encounters.Like all of Maxoderm's penis creams, Vivaxa is designed to take effect quickly. A five-to-10 minute application prior to sexual intercourse will delay the user's climax and provide additional stamina from beginning to end. As a topical solution, Vivaxa is also safer for many customers than traditional male enhancement pills. With no known side effects, the formula is well-suited for men concerned with their overall health as well as their sexual health. The company's website outlines a schedule with the recommended frequency for Vivaxa applications during a user's first 12 weeks. For maximum results, Maxoderm suggests that men who use Vivaxa should apply the product four times during the first week, then five times in the second and third weeks. Six applications are advised for the fourth through the sixth weeks, with a gradual reduction down to only three applications during subsequent weeks.